Suppr超能文献

急性疟疾后葡萄糖-6-磷酸脱氢酶活性的变化。

Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria.

机构信息

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia.

Infectious Diseases Division, International Centre for Diarrheal Diseases Research, Bangladesh, Mohakhali, Dhaka, Bangladesh.

出版信息

PLoS Negl Trop Dis. 2022 May 11;16(5):e0010406. doi: 10.1371/journal.pntd.0010406. eCollection 2022 May.

Abstract

Primaquine and tafenoquine are the only licensed drugs with activity against Plasmodium vivax hypnozoites but cause haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Malaria also causes haemolysis, leading to the replacement of older erythrocytes with low G6PD activity by reticulocytes and young erythrocytes with higher activity. Aim of this study was to assess the impact of acute malaria on G6PD activity. Selected patients with uncomplicated malaria were recruited in Bangladesh (n = 87), Indonesia (n = 75), and Ethiopia (n = 173); G6PD activity was measured at the initial presentation with malaria and a median of 176 days later (range 140 to 998) in the absence of malaria. Among selected participants (deficient participants preferentially enrolled in Bangladesh but not at other sites) G6PD activity fell between malaria and follow up by 79.1% (95%CI: 40.4 to 117.8) in 6 participants classified as deficient (<30% activity), 43.7% (95%CI: 34.2 to 53.1) in 39 individuals with intermediate activity (30% to <70%), and by 4.5% (95%CI: 1.4 to 7.6) in 290 G6PD normal (≥70%) participants. In Bangladesh and Indonesia G6PD activity was significantly higher during acute malaria than when the same individuals were retested during follow up (40.9% (95%CI: 33.4-48.1) and 7.4% (95%CI: 0.2 to 14.6) respectively), whereas in Ethiopia G6PD activity was 3.6% (95%CI: -1.0 to -6.1) lower during acute malaria. The change in G6PD activity was apparent in patients presenting with either P. vivax or P. falciparum infection. Overall, 66.7% (4/6) severely deficient participants and 87.2% (34/39) with intermediate deficiency had normal activities when presenting with malaria. These findings suggest that G6PD activity rises significantly and at clinically relevant levels during acute malaria. Prospective case-control studies are warranted to confirm the degree to which the predicted population attributable risks of drug induced haemolysis is lower than would be predicted from cross sectional surveys.

摘要

伯氨喹和他非诺喹是唯一具有抗疟原虫休眠子活性的已许可药物,但会导致葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症患者发生溶血。疟疾也会导致溶血,导致衰老的低 G6PD 活性红细胞被网织红细胞和高 G6PD 活性的年轻红细胞所取代。本研究旨在评估急性疟疾对 G6PD 活性的影响。在孟加拉国(n=87)、印度尼西亚(n=75)和埃塞俄比亚(n=173)招募了患有无并发症疟疾的选定患者;在没有疟疾的情况下,在最初出现疟疾时测量 G6PD 活性,并在中位数 176 天后(范围 140 至 998 天)再次测量。在选定的参与者中(优先在孟加拉国招募的缺乏参与者,但在其他地点没有),6 名被归类为缺乏症(<30%的活性)的参与者中,G6PD 活性在疟疾和随访之间下降了 79.1%(95%CI:40.4 至 117.8),39 名中间活性(30%至<70%)的个体下降了 43.7%(95%CI:34.2 至 53.1),290 名 G6PD 正常(≥70%)参与者下降了 4.5%(95%CI:1.4 至 7.6)。在孟加拉国和印度尼西亚,G6PD 活性在急性疟疾期间明显高于在同一个体进行随访时的水平(分别为 40.9%(95%CI:33.4-48.1)和 7.4%(95%CI:0.2 至 14.6)),而在埃塞俄比亚,急性疟疾期间 G6PD 活性降低了 3.6%(95%CI:-1.0 至-6.1)。在出现间日疟或恶性疟感染的患者中,G6PD 活性的变化是明显的。总体而言,6 名严重缺乏症患者中有 4 名(4/6)和 39 名中间缺乏症患者中有 87.2%(34/39)在出现疟疾时其活性正常。这些发现表明,G6PD 活性在急性疟疾期间显著升高,并达到临床相关水平。需要进行前瞻性病例对照研究,以确认药物诱导性溶血的预测人群归因风险在多大程度上低于横断面调查的预测值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d1d/9094517/a45cd23eae04/pntd.0010406.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验